Your browser doesn't support javascript.
loading
Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?
Iles, Kathleen A; Thornton, Madeline; Park, Jihye; Roberson, Mya; Spanheimer, Philip M; Ollila, David W; Gallagher, Kristalyn.
Afiliación
  • Iles KA; Department of Surgery, 2332University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Thornton M; Department of Surgery, 2332University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Park J; Department of Epidemiology, 2332University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Roberson M; Department of Epidemiology, 2332University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Spanheimer PM; Department of Surgical Oncology, 2332University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Ollila DW; Department of Surgical Oncology, 2332University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Gallagher K; Department of Surgical Oncology, 2332University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Am Surg ; 88(3): 471-479, 2022 Mar.
Article en En | MEDLINE | ID: mdl-34587799

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma Intraductal no Infiltrante / Antineoplásicos Hormonales / Terapia Neoadyuvante / Pandemias / COVID-19 Tipo de estudio: Guideline País/Región como asunto: America do norte Idioma: En Revista: Am Surg Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma Intraductal no Infiltrante / Antineoplásicos Hormonales / Terapia Neoadyuvante / Pandemias / COVID-19 Tipo de estudio: Guideline País/Región como asunto: America do norte Idioma: En Revista: Am Surg Año: 2022 Tipo del documento: Article